220436-06-6

Usage

Uses

Used in Pharmaceutical Research:
[2-Chloro-4-(1-methyl-1H-pyrazol-3-yl)-phenyl]-(5H,11H-pyrrolo[2,1-c]-[1,4]benzodiazepine-10-yl)-methanone is used as a potential candidate in pharmaceutical research for its possible biological activity. [2-Chloro-4-(1-methyl-1H-pyrazol-3-yl)-phenyl]-(5H,11H-pyrrolo[2,1-c]-[1,4]benzodiazepine-10-yl)-methanone's unique structure and properties make it a promising candidate for further study and development in the field of drug discovery and design.
Used in Chemical Synthesis:
In the chemical industry, [2-Chloro-4-(1-methyl-1H-pyrazol-3-yl)-phenyl]-(5H,11H-pyrrolo[2,1-c]-[1,4]benzodiazepine-10-yl)-methanone may be utilized as an intermediate or building block in the synthesis of other complex organic compounds. Its unique structure could be exploited to create novel molecules with specific properties and applications in various fields, such as materials science, agrochemistry, or specialty chemicals.

Upstream product

• 332109-91-8 2-chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoyl chloride 
• 22162-53-4 10,11-dihydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine 
• 220436-05-5 2-Chloro-4-(1-methyl-1H-pyrazol-3-yl)-benzoic Acid 
• 79-37-8 oxalyl dichloride 

Relevant academic research and scientific papers

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.

Tricyclic vasopressin agonists

This invention relates to new compounds selected from those of the general formula (I), or a pharmaceutically acceptable salt, ester or prodrug form thereof: wherein D, E and G are N or CH, which serve as vasopressin agonists and are useful in treating disorders such as diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, and the inability to temporarily delay urination and pharmaceutical compositions and methods for same.

Process for converting propargylic amine-N-oxides to enaminones

This invention concerns the use of a hydroxylic solvent in the preparation of enaminones from the corresponding amine N-oxides or propargylic amines via the general process outlined below: STR1